This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Swedish Orphan Biovitrum

Drug Names(s): Bucelipase alfa (INN), rhBSSL

Description: Exinalda is a recombinant version of a human fat-digesting enzyme (bile salt stimulated lipase; BSSL). It is administered to replace the enzyme in patients with fat malabsorption. The enzyme is the same one used in Kiobrina.

Deal Structure: In August 2005, Biovitrum obtained the rights to Exinalda (BSSL) through the acquisition of Arexis.

In November 2009, Biovitrum and the shareholders of Swedish Orphan reached an agreement under which Biovitrum will acquire 100 per cent of the shares and warrants in Swedish Orphan. The new group will be called Swedish Orphan Biovitrum.

Exinalda News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug